Navigation Links
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Date:2/28/2011

patients who reported two or more flares by 66% (p<0.0001).

Detailed data from both the PRE-SURGE 2 and RE-SURGE studies will be presented at future scientific conferences.  The safety and efficacy of ARCALYST in the gout setting have not been evaluated by the U.S. Food and Drug Administration.  ARCALYST is not approved for use in gout.

About the PRE-SURGE 2 StudyThe Global PRE-SURGE 2 (PREventative Study against URate-lowering drug-induced Gout Exacerbations) study was a double-blind, placebo-controlled study which evaluated the number of gout flares per patient over the first 16 weeks following initiation of allopurinol therapy.  The trial was conducted in South Africa, Germany, and parts of Asia. In the trial, a gout flare was defined as patient-reported acute articular pain typical of a gout attack that was deemed (by the patient and/or the investigator) to require treatment with an anti-inflammatory therapeutic and involved at least three of four signs/symptoms (joint swelling, redness, tenderness, and pain) and one or more of the following: rapid onset of pain, decreased range of motion, joint warmth, or other symptoms similar to a prior gout flare.  A total of 248 patients were randomized on a 1:1:1 basis to receive one of the following treatment regimens:

  • ARCALYST 160 mg as an initial subcutaneous loading dose, followed by weekly 80 mg subcutaneous injections for a total of 16 weeks
  • ARCALYST 320 mg as an initial subcutaneous loading dose, followed by weekly 160 mg subcutaneous injections for a total of 16 weeks
  • Subcutaneous weekly placebo injections for 16 weeks

    • Primary and key secondary endpoint results were as follows:PlaceboARCALYST® (rilonacept) 80 mgARCALYST® (rilonacept) 160 mg n82

    82

    84*Primary endpointMean # of flares per patient (% reduction compared to placebo)1.23

    0.35

    (72% reduction)


    '/>"/>

    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
    2. New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays
    3. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
    4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
    5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
    6. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
    7. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
    8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
    9. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
    10. MADIT-CRT Trial Meets Primary Endpoint
    11. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2013)... May 21, 2013  Lakeland Industries, Inc. (NASDAQ: ... of industrial protective clothing for industry, municipalities, healthcare ... local levels, today announced that the Company accepted ... Senior Credit Facility subject to certain terms and ... financing.  However, no assurances can be given that ...
    (Date:5/21/2013)... , 21 de mayo de 2013 ... cuyas compañías filiales incluyen OMNIlife science®, Inc., Enztec, Ltd. ... experimentados para su junta. Guy Mayer, un ejecutivo ortopédico ... David Johnson , un experto ... Antes de unirse a OSI como ...
    (Date:5/21/2013)... Inc. (NASDAQ: LCAV ), a leading provider of ... announces that all nominees to the company,s Board of Directors ... stockholders.  These Directors are: , William F. ... Investment Counsel , John C. Hassan ... F. Heizer III , Chairman of Manus Health Systems, ...
    Breaking Medicine Technology:Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 2Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 3Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 4Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 5Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 6Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 7Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 8Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 9Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 10Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 11Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 12Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 13Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3LCA-Vision Reports on Annual Meeting of Stockholders 2LCA-Vision Reports on Annual Meeting of Stockholders 3LCA-Vision Reports on Annual Meeting of Stockholders 4
    ... , SAN DIEGO, Dec. 9 ... that the Company,s Principal Executive Officer, Brian M. Culley, will ... Life Sciences On-line Forum on December 15, 2009 at 9:30 ... audio webcast with slide presentation at www.informedinvestors.com , a ...
    ... Supermarket retailer Giant Eagle® Inc., is receiving an award from ... 12th Annual Cheers Awards reception held in Las Vegas. The ... a superlative standard of excellence for others to follow in ... , The Giant Eagle Pharmacy is being ...
    Cached Medicine Technology:Giant Eagle(R) Pharmacy Receives Award for Operational Excellence 2
    (Date:5/21/2013)... 2013, Paris, France: The Orsiro stent, which is ... biodegradable polymer, demonstrated non-inferiority to the Xience Prime ... in-stent late lumen loss at nine months in ... EuroPCR 2013 today. , The BIOFLOW-II substudy used ... to quantitatively assess neointimal hyperplasia and stent apposition ...
    (Date:5/21/2013)... (PRWEB) May 21, 2013 According to a ... Rethink the Use of Botox,” Botox injections have ... their approval in 2002 (Go to goo.gl/8iYbD). Although it is ... popular with men. The injection makes facial wrinkles less visible ... injection last for about three months. This means that people ...
    (Date:5/21/2013)... Fla. (PRWEB) May 21, 2013 The ... distributed on cable networks and cable channels across the ... episodes on its YouTube channel. The producers of the ... companies in the shipping industry, the manufacturing industry, health-related ... pioneering medical facilities and medical practitioners in all parts ...
    (Date:5/21/2013)... Focus, a non-profit organization striving to improve the living ... Corridor region, is releasing results for its 2013 Creative ... May 23rd at 10:30 a.m. The survey follows ... The survey is a critical component to the organizations’ ... and retain people of diverse backgrounds, cultures and beliefs ...
    (Date:5/21/2013)... MedMar Healing Center announces their participation in the ... Twenty-eight businesses, including MedMar Healing Center, doctors, and clubs, are ... is to raise food to help area kids who have ... recent years. , “We like being able to give ... Douglas Chloupek of MedMar Healing Center. “Taking part in the ...
    Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2
    ... To further protect the safety of patients taking ... developed new and revised quality guidelines for pharmacists who ... compounded medicines has grown in recent years, the need ... preparations are of high quality and purity has become ...
    ... ... Following is the National Council on Disability,s monthly bulletin for December ... NCD,s award-winning Web site ( http://www.ncd.gov ), brings you the latest issues ... go to http://listserv.access.gpo.gov , click on "Online mailing list archives," select ...
    ... Wordelman State Director for AARP Idaho , BOISE, Idaho , ... next steps to take to tackle health care reform, Idaho ,s ... for Idaho ,s state and federal lawmakers to step up to ... solutions as opposed to more roadblocks to addressing this critical issue. ...
    ... from UC Davis Health System identifies for the first time ... in creating and sustaining synapses, the complex chemical signaling system ... Jan.14 issue of the journal Neuron, fills a ... abilities as well as some brain disorders. "We ...
    ... study finds , FRIDAY, Jan. 29 (HealthDay News) -- Genital ... that may help improve treatment and prevention, U.S. researchers say. ... seven separate genital sites in four women infected with herpes ... than one area on 56 percent of days when there ...
    ... BOULDER, Colo. , Jan. 29 elephantjournal.com : Apple,s ... comfortably, on it. You can sit on it. You can drop it. ... is it "green?" , For more, visit elephantjournal.com: , http://w ... r een-ish/ , elephantjournal.com: YOGA STAR HEMALAYAA BEHL: ...
    Cached Medicine News:Health News:National Council on Disability Monthly Bulletin for January 2010 2Health News:National Council on Disability Monthly Bulletin for January 2010 3Health News:National Council on Disability Monthly Bulletin for January 2010 4Health News:National Council on Disability Monthly Bulletin for January 2010 5Health News:National Council on Disability Monthly Bulletin for January 2010 6Health News:National Council on Disability Monthly Bulletin for January 2010 7Health News:National Council on Disability Monthly Bulletin for January 2010 8Health News:National Council on Disability Monthly Bulletin for January 2010 9Health News:Idaho's Health Care Woes Need Solutions, Not More Roadblocks 2Health News:Idaho's Health Care Woes Need Solutions, Not More Roadblocks 3Health News:UC Davis researchers identify brain protein for synapse development 2Health News:Waylon Lewis of elephantjournal.com: iPad: Green?; Yoga Star Hemalayaa Behl 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: